Presentations we supply
- Injection 30 mg
- Injection 100 mg
- Injection 250 mg
- Injection 260 mg
- Injection 300 mg
Tell us whether you need the originator brand or a generic, the strength, pack and quantity, and the destination country.
Send Enquiry for PaclitaxelReference information
Summarised from the product information for Paclitaxel 6 mg/ml concentrate for solution for infusion (UK product information). Always follow the product information approved in your own country.
- Active substance
- Paclitaxel
- Pharmacotherapeutic group
- Antineoplastic agents, taxanes (ATC code L01CD01)
- Authorised uses
- First-line treatment of advanced ovarian cancer, with cisplatin
- Metastatic ovarian cancer after platinum-based therapy has failed
- Adjuvant treatment of node-positive breast cancer after anthracycline and cyclophosphamide
- Locally advanced or metastatic breast cancer, with an anthracycline or with trastuzumab
- Metastatic breast cancer after anthracycline therapy has failed, as a single agent
- Advanced non-small cell lung cancer, with cisplatin
- Advanced AIDS-related Kaposi's sarcoma after liposomal anthracycline therapy has failed
- Storage (unopened)
- Vial before opening: no special temperature storage conditions. Store in the original package in order to protect from light.
- Shelf life (unopened)
- 2 years (vial before opening)
- Container and pack
- Type I glass vials of 5 ml (30 mg), 16.7 ml (100 mg) or 50 ml (300 mg); one vial in each carton
Supply from Bio Bridge Pharma
- The registration route and import licence are confirmed for your destination before we make an offer.
- Documents agreed before you order, such as the batch certificate of analysis and a CoPP where your regulator needs one.
- Named patient supply where the destination country's rules allow it.
Sources
- Product information for Paclitaxel 6 mg/ml concentrate for solution for infusion: www.medicines.org.uk